Titles
- Dual eligible demonstrations: the beneficiary perspective1
- Duchenne muscular dystrophy and related dystrophinopathies: developing drugs for treatment1
- Duke University Hospital: organizational and tactical strategies to enhance patient satisfaction1
- Dupilumab and crisaborole for atopic dermatitis: effectiveness and value : final evidence report and meeting summary1
- During the initial COVID-19 response, HHS personnel who interacted with potentially infected passengers had limited protections1
- Duty hour reform and the outcomes of patients treated by new surgeons: evaluating a new paradigm in surgical training1
- Dying well at home: commissioning quality end-of-life care1
- E-Mail from Joshua Lederberg to Alain Bussard1
- E-Mail from Joshua Lederberg to Alan Schwartz and Michael Bayer1
- E-Mail from Joshua Lederberg to Alan Schwartz, Richard A. Balzano, Michael Bayer, and Roger Basl1
- E-Mail from Joshua Lederberg to Arnold and Aline Ludwig1
- E-Mail from Joshua Lederberg to Arthur Zimmermann1
- E-Mail from Joshua Lederberg to Bill Schneider1
- E-Mail from Joshua Lederberg to Bruce Alberts1
- E-Mail from Joshua Lederberg to Cleto Digiovanni1
- E-Mail from Joshua Lederberg to David L. Heymann1
- E-Mail from Joshua Lederberg to Giuseppe Bertani1
- E-Mail from Joshua Lederberg to Joseph Palma1
- E-Mail from Joshua Lederberg to Melinda K. Baran1
- E-Mail from Joshua Lederberg to Michael Bayer, Alan Schwartz, Richard A. Balzano, Roger Basl, and Alison J. Troutman1